SCHEMBL16693159

SCHEMBL16693159

COc1ccc(CN2CCCc3ccccc32)c(OC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.59
MAPT P10636 6/20 0.54
ALDH1A1 P00352 6/20 0.54
LMNA P02545 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
POLB P06746 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
HPGD P15428 1/20 0.54
TSHR P16473 2/20 0.53
MCOLN3 Q8TDD5 1/20 0.52
KMT2A Q03164 6/20 0.51
TDP1 Q9NUW8 2/20 0.50
MEN1 O00255 4/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MAPK1 P28482 3/20 0.46
USP2 O75604 1/20 0.46
TP53 P04637 1/20 0.46
ALOX12 P18054 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16693153 0.82 MAPT (0.49) KDM4EMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL29483476 0.80 ALDH1A1 (0.60) MAPTALDH1A1LMNASMN1; SMN2POLB
SCHEMBL28743846 0.80 ALDH1A1 (0.60) MAPTALDH1A1LMNASMN1; SMN2POLB
SCHEMBL28643238 0.80 SIGMAR1 (0.55) KDM4EALDH1A1LMNASMN1; SMN2POLB
SCHEMBL29483473 0.80 SIGMAR1 (0.55) KDM4EALDH1A1LMNASMN1; SMN2POLB
SCHEMBL8373325 0.79 MTNR1A (0.52) KDM4EALDH1A1LMNATSHRKMT2A
SCHEMBL27923217 0.74 ACHE (0.56) KDM4EALDH1A1L3MBTL1TSHRKMT2A
SCHEMBL13652219 0.74 KDM4E (0.44) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL1328605 0.74 KMT2A (0.44) KDM4EMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL10640944 0.73 KDM4E (0.53) KDM4EMAPTALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 US disclosed
WO-2015066371-A1 SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2015-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 KDM4E 376/4885MAPT 2871/4885ALDH1A1 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.